BioSpace News Archive

DENTSPLY SIRONA Inc., announced that its Board of Directors declared a quarterly cash dividend of $0.125 per share of common stock, an indicated annual rate of $0.50 per share.

Hepion Pharmaceuticals, Inc. announces that its Chief Medical Officer, Todd Hobbs, MD, gave a clinical presentation entitled “Recofilstat (CRV431): A liver-targeting drug candidate for NASH and HCC” today at the 5th Global NASH Congress.

Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its regulatory progress in Europe and any market accepting the CE mark.

Findings from the Integra Connect Database (ICD) Retrospective Observational Study to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting.

INOVIO’s DNA medicines immunotherapy in combination with Libtayo ® elicits vaccine-associated immune responses when administered with RT/TMZ to newly diagnosed GBM patients.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 9, 2022 , at 11:30 a.m.

Agilent Technologies Inc. (NYSE: A) today announced a collaboration agreement with APC Ltd. , in which the companies commit to working towards combining their technologies to provide unique workflows to customers that support automated process analysis via liquid chromatography (LC).

Oak Hill Bio (“Oak Hill”), a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases, today announced that members of its senior leadership team will participate in virtual one-on-one meetings with investors at the upcoming 2022 Wells Fargo Private Biotech Symposium.

VistaGen will present at upcoming William Blair 42 nd Annual Growth Stock Conference and Jefferies Global Healthcare Conference.

Pharmascience Canada, a division of Pharmascience Inc. is proud to launch PRpms-TERIFLUNOMIDE, a generic drug with demonstrated bioequivalence to the brand name AUBAGIO®.